The cost-effectiveness of depression treatment for co-occurring disorders: A clinical trial

被引:8
作者
Watkins, Katherine E. [1 ]
Cuellar, Alison E. [2 ]
Hepner, Kimberly A. [1 ]
Hunter, Sarah B. [1 ]
Paddock, Susan M. [1 ]
Ewing, Brett A. [1 ]
de la Cruz, Erin [3 ]
机构
[1] RAND Corp, Santa Monica, CA 90401 USA
[2] George Mason Univ, Fairfax, VA 22030 USA
[3] Univ Washington, Seattle, WA 98103 USA
关键词
Cost-effectiveness; Cognitive-Behavioral therapy; Depression; COGNITIVE-BEHAVIORAL THERAPY; SUBSTANCE-ABUSE TREATMENT; PRIMARY-CARE; SELF-REPORTS; PSYCHIATRIC OUTPATIENTS; MAJOR DEPRESSION; UNITED-STATES; ALCOHOL; UTILITY; HEALTH;
D O I
10.1016/j.jsat.2013.08.006
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The authors aimed to determine the economic value of providing on-site group cognitive behavioral therapy (CBT) for depression to clients receiving residential substance use disorder (SUD) treatment. Using a quasi-experimental design and an intention-to-treat analysis, the incremental cost-effectiveness and cost-utility ratio of the intervention were estimated relative to usual care residential treatment. The average cost of a treatment episode was $908, compared to $180 for usual care. The incremental cost effectiveness ratio was $131 for each point improvement of the BDI-II and $49 for each additional depression-free day. The incremental cost-utility ratio ranged from $9,249 to $17,834 for each additional quality adjusted life year. Although the intervention costs substantially more than usual care, the cost effectiveness and cost-utility ratios compare favorably to other depression interventions. Health care reform should promote dissemination of group CBT to individuals with depression in residential SUD treatment. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:128 / 133
页数:6
相关论文
共 36 条
  • [1] [Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001
  • [2] [Anonymous], OCC EMPL WAG MAY 201
  • [3] [Anonymous], 2011, BUILDING RECOVERY IM
  • [4] Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients
    Beck, AT
    Steer, RA
    Ball, R
    Ranieri, WF
    [J]. JOURNAL OF PERSONALITY ASSESSMENT, 1996, 67 (03) : 588 - 597
  • [5] The estimation of a preference-based measure of health from the SF-12
    Brazier, JE
    Roberts, J
    [J]. MEDICAL CARE, 2004, 42 (09) : 851 - 859
  • [6] BROWN J, 1992, BRIT J ADDICT, V87, P1013
  • [7] The Looming Expansion And Transformation Of Public Substance Abuse Treatment Under The Affordable Care Act
    Buck, Jeffrey A.
    [J]. HEALTH AFFAIRS, 2011, 30 (08) : 1402 - 1410
  • [8] Temporal stability of the timeline followback interview for alcohol and drug use with psychiatric outpatients
    Carey, KB
    Carey, MP
    Maisto, SA
    Henson, JM
    [J]. JOURNAL OF STUDIES ON ALCOHOL, 2004, 65 (06): : 774 - 781
  • [9] Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol
    Chouinard, G
    Albright, PS
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (04) : 298 - 307
  • [10] The timeline followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties
    Fals-Stewart, W
    O'Farrell, TJ
    Freitas, TT
    McFarlin, SK
    Rutigliano, P
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 2000, 68 (01) : 134 - 144